Cost-Effectiveness Analysis of Treatment for Metastatic Renal Carcinoma in Romania

Alin Liviu Preda¹, Dana Galieta Minca²
1. Public Health and Management Department, Carol Davila University of Medicine and Pharmacy, Bucharest

Corresponding Author:
Alin Liviu Preda
Catedra de Sanatate Publica si Management, Institutul de Sanatate Publica, Str. Dr. Leonte Anastasievici Nr 1-3, Sector 5, cod: 050463, Bucharest, Romania

Received: October 5th, 2018 – Accepted: November 24th, 2018

Abstract
Rationale: In recent years, the cost of several treatment options for renal cancer have been supported by the Romanian healthcare system for both first- and second-line therapies. First-line alternatives through real-life efficacy and amplitude of adverse reactions may influence the efficacy and costs of patients treated with second-line treatment.

Objective: Estimation of the cost-effectiveness and cost-benefit ratio for first-line treatment alternatives: Sunitinib and Pazopanib from the payer’s perspective in the Romanian healthcare system.

Methods and Results: We developed a Markov model to calculate the cost-effectiveness and cost-benefit ratio for 2 cohorts of patients using the results from the COMPARZ study for efficacy (progression-free survival, general survivability and quality of life) and safety and costs from national hospital databases. For an estimated population of 800 patients, Pazopanib has a quantified benefit of 7.19 years in progression-free survival, 11.71 life years gained and 8.97 years of quality-adjusted life-years compared to Sunitinib. The analysis is limited by the accuracy of the national data used and the transposition of general data on efficacy and safety at the local level.

Keywords: cost-effectiveness, cost-utility, renal cancer, reimbursement

Introduction
Epidemiology
As it is one of the most studied types of cancer, many publications regarding renal carcinoma (RC) refer to epidemiology, morphology, therapeutic options and the economic and social burden. Worldwide, the annual incidence of RC increased from 1.5 to 5.9 cases per 100,000 inhabitants [1]. Statistical models indicate that the incidence increased by 1.1% over the past 10 years while the mortality rate for this cause decreased by 0.7% between 2004 and 2015 [2]. The highest incidence is found in Europe and North America. In 2012, 84,400 cases were estimated in the European Union with 34,700 corresponding deaths [3]. Mortality rates are stable in most European countries [4], and in Romania, the prevalence of RC over the last 5 years is around 5,400 cases with an annual incidence of 2000 cases [5].

Etiology
The precise etiology of RC cannot be determined accurately, but several assumptions have been made regarding environmental, physiological and genetic factors. The most frequent factors quoted in the literature are smoking and obesity. Smoking is associated with a 2-fold higher risk increase to develop kidney cancer, this risk being directly proportional to the number of cigarettes smoked [6]. Obesity is closely linked to the occurrence of RC, especially among women [7]. Hypertension and frequent use of analgesics are other risk factors for RC [8].

The costs of treatment for patients diagnosed with RC in Romania continue to increase mainly due to the latest reimbursed therapeutic alternatives. As the financial burden continues to grow, it is essential to understand the therapeutic value of the different treatment alternatives available. This study aims to quantify the cost-effectiveness and cost-utility ratio for the two existing therapeutic alternatives (Sunitinib and Pazopanib) for treating RC as the first-line option from the payer’s perspective.

Materials and Methods
We developed a Markov model to calculate the cost-effectiveness and cost-utility ratios for two cohorts of patients initiated in the first line with either Sunitinib or Pazopanib. In order to compare the two alternatives, we have used indirect clinical efficacy analyses for the two alternatives. The results were quantified in Progression-Free Survival (PFS), Life-Years Gained, and Quality-Adjusted Life-Years (QALY) for Cost-Benefit Analysis. The results were expressed in incremental cost-effectiveness ratios (ICERs) and incremental cost-utility ratios (ICURs).
Structure of model, population and comparator

We used a cohort model that transitions from one state to another and that simulates the natural progression of the disease. For each pre-defined status in the model, we calculated health costs and outcomes for a cohort of 800 patients over one year. We chose the group based on existing data on the number of metastatic cancers treated and reported by the National Health Insurance House as well as international data extrapolated locally. The mathematical model has been developed in Microsoft Excel and follows the logical structure in Figure 1. Characteristics of the cohort of patients are identical to those of the patient population included in the COMPARZ study [9]. The discount level for both costs and utilities was estimated at 3%. The two drugs used for the study are as follows:

- Sunitinib is a drug used in oncology that has a small molecular structure. It acts by inhibiting the enzyme activity of the tyrosine kinase receptor that is over-expressed in metastatic RC. This drug has been marketed in Romania by Pfizer Romania since 2008.
- Pazopanib has the same mechanism of action (tyrosine kinase inhibitor) with an effect on angiogenesis. This drug has been marketed in Romania by Novartis since 2016.

Efficacy

As defined in the COMPARZ clinical trial, the efficacy included in the model is defined as follows:

- Progression-free survival is defined as the time interval between the time of randomization and the time of tumor progression documentation or death as a result of any cause.
- Overall survival is defined as the time interval between the time of randomization and the date of death of any cause.

For patients considered for second-line of treatment, the following options were analysed out of the medications reimbursed in Romania in 2017: Sorafenib, Everolimus, Bevacizumab, Temsirolimus, and Axitinib.

Table 1: PFS and OS as resulted from COMPARZ trial

|        | PFS          | OS           |
|--------|--------------|--------------|
| Pazopanib | 8.3 months (Confidence interval 95% [CI]: 8,3-10,9) | 28.4 months (95% [CI]: 26,2-35,6) |
| Sunitinib | 9.5 months (Confidence interval 95% [CI]: 8,3-11,1) | 29.3 months (95% [CI]: 25,3 -32,5) |

Adverse Effects and Utilities

The adverse effects and the value of the disutility corresponding to each type of adverse effect were used in accordance with the published studies: [9–11] and are summarized in Table 2.

In the COMPARZ study, data on quality of life was recorded using the EQ-5D questionnaire. The questionnaire was administered on day 1, day 28 of each treatment cycle, and completion of the study for each patient. The baseline on day 1 of the study was 0.76 in both the test group and the control group. Progression under treatment decreases the value of utilities by 0.1252, but the administration of the second-line treatment brings a positive impact of 0.005 [12]. Progression of disease in the second-line of treatment decreases utility by 0.075 and is equivalent to the utility for palliative care.

Costs

The treatment costs were calculated in accordance with the therapeutic guidelines regulated by the Ministry of Health Order (1301/2008) and the National Medicines Catalogue of April 2018 as can be seen in Table 3.

The costs for the use of health services and the treatment of adverse events were calculated taking into account the available data from the DRG database and the framework contract tariffs for contracting health services as follows (Table 4):

Results

For a cohort of 800 patients analysed over a 1-year period at a discount rate of 3%, according to PFS and OS data from the COMPARZ study and according to the cost data from the DRG database and standard tariffs for medical services, Pazopanib has a quantified benefit in years of progression-free survival of 7.19; a total of 11.71 years gained and 8.97 quality-adjusted life-years gained compared to Sunitinib as can be seen in Table 5.

From the efficacy point of view, Pazopanib is dominant over Sunitinib in the patient population in which the analysis was performed due to differences in safety (Figure 2).
Table 2: Summarizing the frequency and duration of the adverse effects used in the model and the disutility associated with each adverse effect

| Grade 1 & 2 adverse effects | Sunitinib | Pazopanib | Disutility caused by adverse effects | Average duration of the event (days) |
|-----------------------------|-----------|-----------|---------------------------------------|------------------------------------|
| Total number of therapy cycles administered | 3288      | 3324      |                                       |                                    |
| Number of patients enrolled in the study | 548       | 554       |                                       |                                    |
| Total number of recorded events | 6837      | 6028      |                                       |                                    |
| Fatigue/asthenia            | 925       | 875       | -0.0007                               | 72.04                              |
| Stomatitis                  | 344       | 177       | -0.0018                               | 33.60                              |
| Hypertension                | 246       | 303       | –                                     | 56.92                              |
| Thrombocytopenia            | 638       | 434       | -0.0105                               | 23.52                              |
| Neutropenia                 | 608       | 414       | 0.0223                                | 57.35                              |
| Nausea/Vomiting             | 1101      | 1134      | -0.0151                               | 30.90                              |
| Diarrhea                    | 1345      | 1473      | -0.0261                               | 64.15                              |
| Anemia                      | 505       | 281       | -0.0114                               | 29.63                              |
| Mouth-to-mouth syndrome     | 676       | 420       | 0.0018                                | 68.63                              |
| Proteinuria                 | 80        | 113       | -0.018                                | 55.40                              |
| Rash                        | 300       | 230       | –                                     | –                                  |
| Anorexia                    | 71        | 175       | -0.0082                               | 49.85                              |

| Grade 3 & 4 adverse events |
|-----------------------------|
| Total number of observed events | 626 | 482 |
| Fatigue/asthenia            | 140 | 88  | -0.1237                               | 18.29                              |
| Stomatitis                  | 8   | 10  | -0.0018                               | 33.60                              |
| Hypertension                | 89  | 108 | -0.0084                               | 36.06                              |
| Thrombocytopenia            | 117 | 28  | -0.024                                | 14.02                              |
| Neutropenia                 | 109 | 58  | 0.0223                                | 57.35                              |
| Nausea/Vomiting             | 11  | 16  | -0.0532                               | 11.07                              |
| Diarrhea                    | 44  | 73  | -0.0261                               | 64.15                              |
| Anemia                      | 40  | 21  | –                                     | 12.85                              |
| Mouth-to-mouth syndrome     | 63  | 58  | 0.0141                                | 20.00                              |
| Proteinuria                 | 0   | 0   | -0.018                                | 55.40                              |
| Rash                        | 4   | 10  | –                                     | –                                  |
| Anorexia                    | 1   | 13  | -0.0082                               | 49.85                              |

| Source                      | COMPARZ | COMPARZ |

Regarding the progression-free survival, the difference was 7.19 years for the 800 patients considered for the two scenarios, in favor of Pazopanib. The differences are in favor of Pazopanib also for Life-Years Gained and for Quality-Adjusted Life-Years. The cost difference between the two alternatives is 6.5 million RON over one year. The incremental cost for a QALY is 722.3 RON in favor of Pazopanib, as shown in Table 4.

Sensitivity analysis
The sensitivity analysis for the two alternatives was done by adjusting between -20% and +20% for 138 variables that can influence the outcome. The largest variations are resulting from:
- Pazopanib dose variation (200 vs. 400 mg);
- Sunitinib drug administration calendar (2 weeks of treatment followed by one week of drug pause vs. 4 weeks of treatment followed by two weeks of drug pause);
- Pazopanib treatment cost.

The distribution in the cost-utility graph (Figure 3) shows a uniform dissipation of intersection points for the variables considered.
Table 3: Costs of therapeutic alternatives

| Therapeutic alternatives | Treatment cost for 6 weeks (RON) |
|--------------------------|----------------------------------|
| **Sunitinib**            |                                  |
| 50 mg                    | 19.748                           |
| 37.5 mg                  | 15.003                           |
| **Pazopanib**            |                                  |
| 800 mg                   | 15.507                           |
| 600 mg                   | 11.630                           |
| 400 mg                   | 7.753                            |
| **Second-line treatments**|                                  |
| Sorafenib                | 9.482                            |
| Everolimus               | 20.090                           |
| Bevacizumab (Includes treatment administration costs) | 29.897 |
| Temsirolimus             | 19.552                           |
| Axitinib                 | 25.105                           |

Table 4: Medical services costs

| Cost-type                                | Value (RON) |
|------------------------------------------|-------------|
| Hospitalization episode in the oncology department | 998         |
| Visiting the oncologist (ambulatory care)  | 20.4        |
| Palliative service at home               | 65          |
| Payment of intensive care services       | 5963        |
| Payment for hospitalization episode with surgical intervention | 2656 |
| Palliative surgery                       | 2305        |
| **Laboratory tests**                     |             |
| Hemogram                                 | 14          |
| Set of medical analyses for metabolism evaluation | 175.67     |
| Oncologic markers                        | 145         |
| Thyroid function tests                   | 40          |
| **Imaging investigations**               |             |
| Thoracic or pelvic CT scan               | 175         |
| Radiography                              | 32          |
| Echography                               | 60          |
| MRI                                      | 700         |
| Bone scintigraphy                        | 35          |

Table 5: Results of Sunitinib vs. Pazopanib

|                              | Sunitinib | Pazopanib |
|------------------------------|-----------|-----------|
| Progression-Free Survival Life Years (PFSLY) | 570.69 | 577.88 |
| Overall Survival (Life Years) | 721.32 | 733.04 |
| Quality-Adjusted Life-Years (QALYs) | 497.84 | 506.81 |
| Costs of first-line treatment | 66271079.45 | 57998473.94 |
| Adverse events costs for first-line treatment | 1127299.24 | 988869.31 |
| Pre-progression costs | 67398378.69 | 58987343.25 |
| Costs of second-line treatment | 12932711.77 | 14865966.38 |
| Total costs without discount | 80331090.46 | 73853309.63 |
| Incremental results of Pazopanib vs Sunitinib | — | (901318.06) |
| ICER - PLYs | — | (553011.69) |
| ICER - QALYs | — | (722296.54) |

Table 6: Cost-effectiveness and cost-utility ratio for the two therapeutic alternatives

|                              | Pazopanib vs. Sunitinib |
|------------------------------|-------------------------|
| Incremental PFSLY            | −7.19                   |
| Incremental LY              | −11.71                  |
| Incremental QALYs           | −8.97                   |
| Incremental cost            | 6477781                 |
| Incremental cost per PFSLY gained | −901.318     |
| Incremental cost per LY gained | −553.012     |
| Incremental cost per QALY gained | −722.297    |

Discussions and Conclusions

This analysis provides information on the cost-effectiveness of 2 therapeutic alternatives reimbursed for the treatment of metastatic renal cancer in Romania as first-line of treatment alternatives. In line with the results of the COMPARZ study, administration of the 4-week treatment with a 2-week rest period and measurement of quality of life outcomes on the last day of the 4-week cycle may lead to alteration of the measurements. If the measurement of the quality of life was achieved during the therapeutic period, the results of the comparison of the two drugs might differ. Given that differences in clinical efficacy or quality of life for the two drugs are not very high, we estimate that the only major difference can be given by the differences between the compensation values for the two drugs studied. Also, the cost-effectiveness of the two evaluated alternatives has an impact on the subsequent costs for the following treatment lines as therapies reimbursed for second-line are considerably more expensive than the two alternatives studied.
Conflict of Interest

The authors confirm that there are no conflicts of interest.

References

1. Gupta K, Miller JD, Li JZ, et al. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treat Rev. 2008, Vol. 34, 3.
2. Institute, National Cancer. SEER. [Interactive] May 2018. https://seer.cancer.gov/statfacts/html/kidrp.html.
3. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013, Vol. 49, 6.
4. Znaor A, Lortet-Tieulent J, Laversanne M, Jamal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015, Vol. 67, 3.
5. Organization, World Health. International Agency for Research on Cancer. Cancer Today [Interactive] WHO, May 2018. http://gco.iarc.fr/today/online-analysis-multibars?mode=cancer&mode_populati on=who&population=642&sex=&cancer=29&type=2&statistic=2 &p_revalence=1&color_palette=default.
6. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P. Renal cell carcinoma in relation to cigarette smoking: meta-analysis of 24 studies. Int J Cancer. 2005, Vol. 114, 1.
7. van Dijk BA, Schouten LJ, Kimeney LA, Goldbohm RA, van den Brandt PA. Relation of height, body mass, energy intake, and physical activity to risk of renal cell carcinoma: results from the Netherlands Cohort Study. Am J Epidemiol. 2004, Vol. 160, 12.
8. Corrao G, Scotti L, Bagnardi V, Sega R. Hypertension, antihypertensive therapy and renal-cell cancer: a meta-analysis. Curr Drug Saf. 2007, Vol. 2, 2.
9. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. 2013, Vol. 369, 8.
10. Atkinson BJ, Kalra S, Wang X, et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. J Urol. 2014;191(3):611–618. 2014, Vol. 191, 3.
11. Bracarda S, Iacovelli R, Boni L, et al. Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis. Annals of oncology Official journal of the European Society for Medical Oncology / ESMO. 2015, Vol. 26, 10.
12. Cella D, Li JZ, Cappelleri JC, et al. Quality of life in patients with metastatic renal cell carcinoma treated with sunitinib or interferon alfa: results from a phase III randomized trial. J Clin Oncol. 2008, Vol. 26, 22.
13. JP, Burke. Incidence, annualized cost, and utilization burden in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009, Vol. 29, Suppl.
14. Tsivian M, Moreira DM, Caso JR, et al. Cigarette smoking is associated with advanced renal cell carcinoma. J Clin Oncol. 2011, Vol. 29, 15.
15. DeVita VT Jr HS, Rosenberg SA. Cancer Principles and Practice of Oncology (ed 9th). Philadelphia: Lippincott Williams & Wilkins; 2011.
16. Choyke PL, Glenn GM, Walther MM, Zbar B, Linehan WM. Hereditary renal cancers. Radiology. 2003, Vol. 226, 1.
17. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004, Vol. 22, 4.
18. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The Use of the Nitrogen Mustards in the Palliative Treatment of Carcinoma – with Particular Reference to Bronchogenic Carcinoma. Cancer. 1, 1948, Vol. 4.
19. Gold M, Siegel J, Russell L, Weinstein M, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
20. Hoyle MW, Henley W. Improved curve fits to summary survival data: application to economic evaluation of health technologies. BMC Med Res Methodol. 2011, Vol. 11, 139.
21. James Larkin, Abby Paine, Grace Foley, Stephen Mitchell & Connie Chen. First-line treatment in the management of advanced renal cell carcinoma: systematic review and network meta-analysis. Expert Opinion on Pharmacotherapy. 2015, Vol. 16, 13.
22. Benedict A, Remak E, Kreif N, Munir U. Economic Evaluation of SUTENT® (sunitinib malate) for the First-line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in the US. 2009.
23. Lee JL, Kim MK, Park I, et al. Randomized phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type Renal cell carcinoma: RESTORE trial. Annals of oncology. 2015, Vol. 26, 13.